Theravance Biopharma, Inc. (TBPH)
17.07
+0.04
(+0.23%)
USD |
NASDAQ |
Sep 02, 16:00
17.07
0.00 (0.00%)
After-Hours: 20:00
Theravance Biopharma Cash from Operations (Annual) : 238.54M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 238.54M |
| December 31, 2024 | -11.54M |
| December 31, 2023 | -27.00M |
| December 31, 2022 | -186.99M |
| December 31, 2021 | -207.86M |
| December 31, 2020 | -250.40M |
| December 31, 2019 | -238.20M |
| December 31, 2018 | -112.87M |
| Date | Value |
|---|---|
| December 31, 2017 | -201.05M |
| December 31, 2016 | -98.99M |
| December 31, 2015 | -168.86M |
| December 31, 2014 | -175.16M |
| December 31, 2013 | -120.96M |
| December 31, 2012 | -119.11M |
| December 31, 2011 | -83.43M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Zymeworks, Inc. | -33.00M |
| Viatris, Inc. | 2.316B |
| Ocular Therapeutix, Inc. | -204.88M |
| ANI Pharmaceuticals, Inc. | 185.22M |
| Corcept Therapeutics, Inc. | 142.00M |